stemcellindex.com
Stem Cell Stocks (*RXSTM)
First embryonic stem-cell trial placed on hold by FDA
Nature.com (subscription) - Aug 19, 2009
Six months after giving it the green light, the US Food and Drug Administration has told Geron to put plans for a clinical trial in spinal cord injury on ...
Study Using Embryonic Stem Cells Is Delayed
New York Times - Aug 18, 2009
By BLOOMBERG NEWS The Geron Corporation said on Tuesday that regulators had held up its study of a therapy for injured spinal cords before even one patient ...
Human tests of Geron's spinal-cord medication put on hold
San Jose Mercury News - - Aug 18, 2009
In a setback for Menlo Park-based Geron, the company announced Tuesday that federal authorities have put on hold its groundbreaking test on ...
Geron: FDA delays 1st trial of stem cell treatment
Forbes - Aug 18, 2009
AP , 08.18.09, 08:41 AM EDT MENLO PARK, Calif. -- Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer
First embryonic stem-cell trial placed on hold by FDA
Nature.com (subscription) - Aug 19, 2009
Six months after giving it the green light, the US Food and Drug Administration has told Geron to put plans for a clinical trial in spinal cord injury on ...
Study Using Embryonic Stem Cells Is Delayed
New York Times - Aug 18, 2009
By BLOOMBERG NEWS The Geron Corporation said on Tuesday that regulators had held up its study of a therapy for injured spinal cords before even one patient ...
Human tests of Geron's spinal-cord medication put on hold
San Jose Mercury News - - Aug 18, 2009
In a setback for Menlo Park-based Geron, the company announced Tuesday that federal authorities have put on hold its groundbreaking test on ...
Geron: FDA delays 1st trial of stem cell treatment
Forbes - Aug 18, 2009
AP , 08.18.09, 08:41 AM EDT MENLO PARK, Calif. -- Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer
Bizjournals.com - Aug 7, 2009
Opexa Therapeutics Inc. has signed a deal with pharmaceutical giant Novartis to develop the company's stem cell technology. As part of the agreement, ...
Opexa sells stem cell tech to Novartis; shares zoom
Reuters - - Aug 7, 2009
BANGALORE, Aug 7 (Reuters) - Opexa Therapeutics Inc (OPXA.O) said Swiss drugmaker Novartis (NOVN.VX) acquired its preclinical-stage ...
Biotech/Pharma Stocks Sector Close-Up; Stem Cell Stocks on the ...
InvestorIdeas.com (press release) - Aug 7, 2009
POINT ROBERTS, Wash. - August 7, 2009 - www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, ...
Opexa Therapeutics Inc (NASDAQ:OPXA) Is The Most Active
TransWorldNews (press release) - Aug 7, 2009
Opexa Therapeutics Inc (NASDAQ:OPXA) jumped 205.6% in an opening trade and currently trades at $1.44 on a high volume 502k shares compared to total daily ...
Opexa Announces Stem Cell Agreement with Novartis
Woodlands Online, LLC - Aug 7, 2009
THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for multiple sclerosis (MS), ...
Novartis scoops up Opexa's stem cell program in $50M deal
FierceBiotech - - Aug 7, 2009
Shares of Opexa Therapeutics got a badly needed bump after the biotech announced that it had struck a deal to sell its preclinical stem cell technology to ...
Cell Therapeutics, Inc Stem Cell Companies Stem Cell Stocks BioMimetic Therapeutics (BMTI) Pluristem Therapeutics-PTSI Osiris Therapeutics-OSIR Cytori Therapeutics, Inc. ThermoGenesis (KOOL) Nutra Pharma (OTCBB:NPHC) Human Embryonic Stem Cell Market RTI Biologics (RTIX) Aastrom Biosciences -ASTM XOMA 052 Designated Orphan Drug by FDA ...
Published:Wed, 04 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, ......
Published:Wed, 04 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, ......
XOMA to Announce 2010 Second Quarter Fi...
Published:Mon, 02 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, Augus......
Published:Mon, 02 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, Augus......
XOMA 052 Orphan Drug Designation for Be...
Published:Thu, 29 Jul 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medic......
Published:Thu, 29 Jul 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medic......
Biotech Stocks: Depomed, Dendreon lead ...
Published:Wed, 04 Aug 2010 07:55:59 -0700
Depomed lead gains among drug stocks a day after it said Pfizer will not file a patent infringement lawsuit to prevent the launch of a painkiller.......
Published:Wed, 04 Aug 2010 07:55:59 -0700
Depomed lead gains among drug stocks a day after it said Pfizer will not file a patent infringement lawsuit to prevent the launch of a painkiller.......
Trader Favorite Dendreon Spikes On Prov...
Published:Wed, 04 Aug 2010 08:00:00 -0700
After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales fi......
Published:Wed, 04 Aug 2010 08:00:00 -0700
After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales fi......
